## **Product** Data Sheet

## **Arborinine**

Cat. No.: HY-128912 CAS No.: 5489-57-6 Molecular Formula:  $C_{16}H_{15}NO_4$ Molecular Weight: 285.29

Target: Histone Demethylase

Pathway: Epigenetics

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	Arborinine is a potent and orally activeLSD1 inhibitor. Arborinine increases the expression of H3K4me1/2, H3K9me1/2, E-cad protein and decreases the expression of UBE2O protein level. Arborinine induces cell cycle arrest at S phase. Arborinine shows antitumor activity [1][2].
IC <sub>50</sub> & Target	LSD1
In Vitro	Arbarining (0. 5. 15. 20 µM· 48 b) increases the expression of H2K4mo1/2. H2K9mo1/2. E. cad protoin <sup>[1]</sup>

Arborinine (0, 5, 15, 30  $\mu$ M; 48 h) increases the expression of H3K4me1/2, H3K9me1/2, E-cad protein<sup>[1]</sup>. Arborinine (20  $\mu$ M) decreases the expression of UBE2O protein level in 7860 cells<sup>[1]</sup>.

Arborinine (20  $\mu$ M) induces cell cycle arrest at the S phase and inhibits cell apoptosis [1].

0-100 μΜ

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$ 

7860, A498, 769P, Caki1, OSRC2 cells

 ${\sf Cell\ Proliferation\ Assay}^{[1]}$ 

Cell Line:

Concentration:

Incubation Time:	48, 72 h		
Result:	Showed antiproliferative activity with IC $_{50}$ s of 30.62, 39.09, 15.67, 31.42, 30.35 $\mu$ M at 48 h, 20.92, 27.01, 14.94, 30.26, 17.37 $\mu$ M at 72 h for 786O, A498, 769P, Caki1, OSRC2 cells, respectively.		
Western Blot Analysis <sup>[1]</sup>			
Cell Line:	7860 cells		
Concentration:	0, 5, 15, 30 μΜ		
Incubation Time:	48 h		
Result:	Increased the expression of H3K4me1/2 and H3K9me1/2 protein in a dose-dependent manner.		

Cell Cycle Analysis<sup>[1]</sup>

	Cell Line:			
	Cett Line:	786O and A498 cells		
	Concentration:	20 μΜ		
	Incubation Time:			
	Result:	Induced increased population in S phase and decreased population in G1 phase, significantly inhibited both early and late apoptosis of ccRCC cells		
In Vivo		Arborinine (40, 80 mg/kg; p.o.; for 21 days) shows antitumor activity in mouse <sup>[2]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	BALB/c nude mice (SGC-7901 cells and SGC-7901/ADR cells) <sup>[2]</sup>		
	Dosage:	40, 80 mg/kg		
	Administration:	P.o.; for 21 days		
	Result:	Inhibited the growth of tumors while unchanged the body weights.		

## **REFERENCES**

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

<sup>[1].</sup> Feng C, et al. Arborinine from Glycosmis parva leaf extract inhibits clear-cell renal cell carcinoma by inhibiting KDM1A/UBE2O signaling. Food Nutr Res. 2022 Sep 16;66.

<sup>[2].</sup> Chu Y, et al. Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells. Invest New Drugs. 2021 Jun;39(3):627-635.